EAHAD 2016: Highlight interviews

February 10, 2016

  • Share this post:

Highlight 1: Von Willebrand Disease

– Carolyn Millar, MD, Hammersmith Hospital, London: The necessity of VWD subclassification

– Vuokko Jokela, MD, Helsinki University Central Hospital: Impact of platelet function on clinical phenotypes in Von Willebrand Disease: re-evaluation of 83 patient with historical diagnosis

– Lucia Rugeri, MD, Hôpital Cardiologique, Lyon: Genotyping might help therapeutic decision making in patients with Von Willebrand Disease type 2B (VWD2B)

Click here to go to this highlight

 

Highlight 2: Hemophilia A

– Elena Santagostino, MD PhD, Maggiore Hospital Policlinico, Milan: TGA for testing of hemostatic effectiveness of fVIII concentrates in patients with Hemophilia A and inhibitors: in vitro results from the predicTGA study

– Prof. Cédric Hermans, MD, St-Luc University Hospital, Brussels: Updates on the SIPPET, FranceCoag and RODIN studies: the relationship between specific FVIII concentrate and inhibitor formation

– Katharina Holstein, MD, University Medical Centre, Hamburg: Expression and release of platelet protein disulfide isomerase (PDI) is increased in patients with hemophilia A

– Prof. Karin Fijnvandraat, MD, Academisch Medisch Centrum, Amsterdam: Case report – Multidisciplinary approach, treatment of inhibitors with ITI

Click here to go to this highlight

 

Highlight 3: Musculoskeletale complicaties

– Prof. Alok Srivastava, MD, Christian Medical College, Vellore: Low dose prophylaxis and treatment of joint inflammation caused by joint bleeds

– Mehdi Osooli, M.Sc., Lund University: Joint outcomes in mild hemophilia: a register based study

– Björn Rosengren, MD PhD, Skåne University Hospital, Malmö: Managing osteoporosis in hemophilia patients

Click here to go to this highlight

 

Adviescommissie:

Prof. Karin Fijnvandraat, AMC Amsterdam

Dr. Marjon Cnossen, Erasmus MC Rotterdam

Prof. Karina Meijer, UMCG Groningen

 

The EAHAD 2016 highlights are financially supported by Bayer B.V.